The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
作者信息
Jedlicka Paul
机构信息
a Department of Pathology , University of Colorado Denver, Anschutz Medical Campus , Aurora , CO , USA.
出版信息
Expert Opin Ther Targets. 2017 Nov;21(11):997-999. doi: 10.1080/14728222.2017.1391791. Epub 2017 Oct 13.
Abstract
摘要
相似文献
1
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.KDM3A作为尤因肉瘤和其他癌症治疗靶点的潜力。
Expert Opin Ther Targets. 2017 Nov;21(11):997-999. doi: 10.1080/14728222.2017.1391791. Epub 2017 Oct 13.
2
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.组蛋白去甲基化酶KDM3A是尤文肉瘤中一种受微小RNA-22调控的肿瘤促进因子。
Oncogene. 2015 Jan 8;34(2):257-62. doi: 10.1038/onc.2013.541. Epub 2013 Dec 23.
3
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.组蛋白去甲基化酶KDM3A及其下游靶点MCAM促进尤因肉瘤细胞迁移和转移。
Oncogene. 2017 Jul 20;36(29):4150-4160. doi: 10.1038/onc.2017.44. Epub 2017 Mar 20.
4
Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications.尤因肉瘤：分子病理学最新进展及其治疗意义
Surg Pathol Clin. 2017 Sep;10(3):575-585. doi: 10.1016/j.path.2017.04.001. Epub 2017 Jun 21.
5
Innovative therapies in Ewing Sarcoma.尤文肉瘤的创新疗法。
Adv Anat Pathol. 2014 Jan;21(1):44-62. doi: 10.1097/PAP.0000000000000003.
6
DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.DNA甲基化分析为寻找针对尤因肉瘤的靶向治疗开启了一个新阶段。
Pharmacogenomics. 2017 Sep;18(14):1307-1309. doi: 10.2217/pgs-2017-0017. Epub 2017 Aug 23.
7
Ewing sarcoma treatment.尤因肉瘤的治疗
Eur J Cancer. 2011 Sep;47 Suppl 3:S366-7. doi: 10.1016/S0959-8049(11)70206-4.
8
Jumonji histone demethylases as emerging therapeutic targets.Jumonji 组蛋白去甲基酶作为新兴的治疗靶点。
Pharmacol Res. 2016 Mar;105:146-51. doi: 10.1016/j.phrs.2016.01.026. Epub 2016 Jan 24.
9
Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression.组蛋白去甲基化酶 KDM3（JMJD1）在转录调控和癌症进展中的作用。
Adv Exp Med Biol. 2023;1433:69-86. doi: 10.1007/978-3-031-38176-8_4.
10
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.儿童肿瘤中 Jumonji 结构域组蛋白去甲基酶家族的生物学与靶向治疗：临床前概述。
Expert Opin Ther Targets. 2019 Apr;23(4):267-280. doi: 10.1080/14728222.2019.1580692. Epub 2019 Feb 26.
引用本文的文献
1
Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis.多组学分析揭示了尤因肉瘤转移所涉及的关键因素。
Mol Oncol. 2025 Apr;19(4):1002-1028. doi: 10.1002/1878-0261.13788. Epub 2025 Jan 5.
2
Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.尤因肉瘤中的表观遗传和转录信号——疾病病因与治疗机遇
Biomedicines. 2022 Jun 5;10(6):1325. doi: 10.3390/biomedicines10061325.
3
KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development.KDM3A 介导的 SP1 激活 PFKFB4 转录促进骨肉瘤有氧糖酵解并增强肿瘤发展。
BMC Cancer. 2022 May 19;22(1):562. doi: 10.1186/s12885-022-09636-8.
4
KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma.KDM5A和PHF2正向调控受EWS/Fli1抑制的促转移基因的表达，并促进尤因肉瘤的生长和转移特性。
Oncotarget. 2020 Oct 27;11(43):3818-3831. doi: 10.18632/oncotarget.27737.
5
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.KDM3A/Ets1/MCAM轴促进横纹肌肉瘤的生长和转移特性。
Genes Cancer. 2020;11(1-2):53-65. doi: 10.18632/genesandcancer.200.
本文引用的文献
1
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.组蛋白去甲基化酶 KDM3A 依赖性 AP-1 转录活性对 PI3K 激活诱导的肝肿瘤发生的影响。
Oncogene. 2017 Nov 9;36(45):6262-6271. doi: 10.1038/onc.2017.222. Epub 2017 Jul 10.
2
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.组蛋白去甲基化酶KDM3A及其下游靶点MCAM促进尤因肉瘤细胞迁移和转移。
Oncogene. 2017 Jul 20;36(29):4150-4160. doi: 10.1038/onc.2017.44. Epub 2017 Mar 20.
3
Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.EWSR1-FLI1活性的细胞间异质性决定了尤因肉瘤细胞的增殖/迁移选择。
Oncogene. 2017 Jun 22;36(25):3505-3514. doi: 10.1038/onc.2016.498. Epub 2017 Jan 30.
4
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.赖氨酸去甲基化酶KDM3A通过靶向组蛋白和非组蛋白p53调节乳腺癌细胞的侵袭和凋亡。
Oncogene. 2017 Jan 5;36(1):47-59. doi: 10.1038/onc.2016.174. Epub 2016 Jun 6.
5
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.KDM3A-KLF2-IRF4轴维持骨髓瘤细胞的存活。
Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258.
6
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.组蛋白去甲基化酶JMJD1A对c-Myc表达的调控对于前列腺癌细胞的生长和存活至关重要。
Oncogene. 2016 May 12;35(19):2441-52. doi: 10.1038/onc.2015.309. Epub 2015 Aug 17.
7
Advances in the development of histone lysine demethylase inhibitors.组蛋白赖氨酸去甲基化酶抑制剂的研发进展
Curr Opin Pharmacol. 2015 Aug;23:52-60. doi: 10.1016/j.coph.2015.05.009. Epub 2015 Jun 5.
8
Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.用于癌症治疗的溴结构域和额外末端结构域抑制剂（BETi）：染色质结构的化学调控
Cold Spring Harb Perspect Biol. 2014 Dec 1;6(12):a018663. doi: 10.1101/cshperspect.a018663.
9
The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.组蛋白去甲基化酶JMJD1A通过上调长链非编码RNA MALAT1的表达来诱导细胞迁移和侵袭。
Oncotarget. 2014 Apr 15;5(7):1793-804. doi: 10.18632/oncotarget.1785.
10
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.组蛋白去甲基化酶KDM3A是尤文肉瘤中一种受微小RNA-22调控的肿瘤促进因子。
Oncogene. 2015 Jan 8;34(2):257-62. doi: 10.1038/onc.2013.541. Epub 2013 Dec 23.
Zotero 插件